Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
Research so far paints a cautiously hopeful picture about using psilocybin to reduce anxiety. Small clinical trials and reviews show that, when psilocybin is given together with careful therapy and support, some people — especially those facing life‑threatening illness — report less anxiety for weeks or months. However, most studies are small or early stage, and scientists say we need bigger, better trials before we can be sure how well it works, who it helps, and how safe it is long term.
This paper describes psychedelic-assisted psychotherapy, which means giving drugs like ketamine, MDMA, psilocybin, LSD or ibogaine together with guided therapy. The authors say this approach has shown promising safety and benefits so far, even for people who did not get better with usual treatments. They also argue that these therapies…
This paper reviews research on three naturally occurring psychedelics: psilocybin, ibogaine, and N,N-dimethyltryptamine (the active part of the brew ayahuasca). It explains that these drugs work on the brain's serotonin system and summarizes growing studies that suggest they might help with problems like post-traumatic stress disorder, major depression, anxiety, and…
